Baptist Health South Florida and the START Center for Cancer Research, the largest global network of fully dedicated, early-phase oncology clinical trial sites, announced plans to form a strategic collaboration.
The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.Â
